Simvastatin After Aneurysmal Subarachnoid Hemorrhage

Completed

Phase N/A Results

Results

There were no significant differences in laboratory-defined transaminitis or myositis between groups. No patients developed clinical symptoms of myopathy or hepatitis. Plasma von Willebrand factor and S100B were decreased 3 to 10 days after SAH (P<0.05) in patients receiving simvastatin versus placebo with the highest mean middle cerebral artery transcranial Doppler velocities being significantly lower in the simvastatin-treated group (103+/-41 versus 149+/-47; P<0.01). In addition, vasospasm was significantly reduced (P<0.05) in the simvastatin-treated group (5 of 19) compared with those who received placebo (12 of 20).